UVA AI Designs Drugs That Adapt to Moving Proteins

Scientists just solved a problem that's been wasting billions of dollars and countless lives: designing drugs for proteins that won't sit still.

Researchers at the University of Virginia School of Medicine developed three AI tools that work together like a dream team for drug discovery. The centerpiece, called YuelDesign, creates new medicines while accounting for how proteins flex and shift shape in real time.

"Think of it this way: Other methods try to design a key for a lock that's sitting perfectly still, but in your body, that lock is constantly jiggling and changing shape," said Dr. Nikolay V. Dokholyan, who led the research. "Our AI designs the key while the lock is moving, so the fit is much more realistic."

The stakes couldn't be higher. Developing a new drug costs around $2.6 billion, and nearly 90% of new medicines fail when they reach human testing. Most failures happen because drugs that look perfect on a computer screen don't work in living bodies, where proteins constantly change shape.

Current AI tools treat proteins like frozen statues. YuelDesign treats them like dancers, designing drug molecules that adapt as proteins move during binding. Two companion tools help: YuelPocket identifies exactly where on a protein a drug should attach, and YuelBond ensures the chemical bonds are accurate.

The technology uses advanced "diffusion models" that simultaneously generate both the protein pocket and the molecule that fits into it. Both structures evolve together during the design process, just like they would inside your body.

The Ripple Effect

The breakthrough could transform treatment for cancer, neurological disorders, and other conditions where current drugs keep hitting dead ends. When the team tested YuelDesign on CDK2, a cancer-related protein, only their tool could capture the critical structural changes that happen when a drug binds.

Dokholyan wants every researcher on Earth to benefit. His team made all three tools freely available to scientists worldwide, no strings attached. "We want to democratize drug discovery," he said. "We want researchers anywhere in the world to be able to use them to tackle the diseases that matter most to their patients."

The tools are already available online, funded by the National Institutes of Health and National Science Foundation. The research team has no financial interest in the work, they're purely focused on getting better medicines to patients faster.

Better drugs could reach patients sooner, cost less to develop, and actually work when they arrive.